Clinuvel Pharmaceutical Forecast, price target & analysts
Clinuvel Pharmaceutical Target price 2025 - Analyst rating & recommendation
Clinuvel Pharmaceutical Classifications & Recommendation:
Clinuvel Pharmaceutical Price Target
| Target Price | A$23.48 |
| Price | A$11.05 |
| Potential |
112.45%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Clinuvel Pharmaceutical 2026 .
The average Clinuvel Pharmaceutical target price is A$23.48.
This is
112.45%
register free of charge
A$39.11
253.96%
register free of charge
A$14.14
27.96%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Clinuvel Pharmaceutical to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2026 of
112.45%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million A$ | 95.02 | 105.19 |
| 0.50% | 10.70% | |
| EBITDA Margin | 49.37% | 43.41% |
| 16.51% | 12.07% | |
| Net Margin | 38.07% | 37.52% |
| 2.00% | 1.43% |
9 Analysts have issued a sales forecast Clinuvel Pharmaceutical 2026 . The average Clinuvel Pharmaceutical sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Clinuvel Pharmaceutical EBITDA forecast 2026. The average Clinuvel Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Clinuvel Pharmaceutical Analysts have issued a net profit forecast 2026. The average Clinuvel Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | 0.72 | 0.79 |
| 2.86% | 9.72% | |
| P/E | 13.65 | |
| EV/Sales | 2.99 |
9 Analysts have issued a Clinuvel Pharmaceutical forecast for earnings per share. The average Clinuvel Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Clinuvel Pharmaceutical...
Current Clinuvel Pharmaceutical Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WILSONS |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| MOELIS AUSTRALIA SECURITIES |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| WILSONS |
Locked
➜
Locked
|
Locked | Jul 18 2025 |
| WILSONS |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
WILSONS:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 08 2025 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
MOELIS AUSTRALIA SECURITIES:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
WILSONS:
Locked
➜
Locked
|
Jul 18 2025 |
|
Locked
WILSONS:
Locked
➜
Locked
|
Jul 17 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Jul 17 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
